Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Access

- PMLiVE

Study reveals new breast cancer genes found in women of African ancestry

More than 240,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

ICR researchers reveal key driver of PARP inhibitor resistance in advanced breast cancer

Currently the most common cancer in the UK, breast cancer affects over 55,000 people annually

- PMLiVE

Johnson & Johnson shares positive results for TAR-200 in high-risk bladder cancer

More than 83,000 cases of bladder cancer are diagnosed in the US every year

- PMLiVE

Free Live Webinar – Uniting Communities for Rare Disease Clinical Trial Success

Join this live webinar focusing on patient recruitment and retention in rare disease trials.

Innovative Trials

- PMLiVE

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains...

Impetus Digital

- PMLiVE

Showing Deep Expertise at ONS

The Medscape Oncology team will be connecting with the oncology nursing community this week in Washington, DC for the ONS Congress 2024.  Medscape Oncology has deep expertise in the oncology...

Medscape Education Global

- PMLiVE

Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot

This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...

Research Partnership

- PMLiVE

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

- PMLiVE

AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer

Approximately 210,000 people worldwide are diagnosed with the disease every year

- PMLiVE

FDA establishes new CDER centre focused on promoting clinical trial innovation

The C3TI will give internal and external parties easier access to information on clinical trial innovation

- PMLiVE

ICR scientists reveal new ways to convert inhibitor-style targeted cancer drugs into degraders

Findings from the study could help researchers create more effective treatments for cancer

- PMLiVE

Novartis gains rights to Arvinas’ prostate cancer therapy in deal worth over $1bn

The transaction also includes the sale of Arvinas’ preclinical AR-V7 programme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links